Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists

Registration

Registration

NCT06818292

Acronym

GLPsy

Study type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

SINGLE

Status

COMPLETED

Enrollment

10

Start

2024-10-21

Primary completion

2024-12-06

Lead sponsor

Nils Opel

Conditions

Healthy

Interventions

BIOLOGICAL:Liraglutide; BIOLOGICAL:Placebo

Results posted

FALSE

Registered primary outcomes

• Neuropsychology: Processing speed [Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months]
• Neuropsychology: Attention [Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months]
• Neuropsychology: Memory [Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months]
• Neuropsychology: Verbal Fluency [Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months]
• MR spectroscopy [Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months]
• Exploratory Proteomics of Autophagy Processes I [Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months]
• Exploratory Proteomics of Autophagy Processes II [Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months]